Expiration date: 01/2027

The composition and form of issue:

The solution is for intramuscular and subcutaneous injection. 1 ml contains:

Imunofan in cancer 50 mcg

excipients: glycine sodium chloride water for injections 

in a contour acheikova package 5 or 10 ampoules in a pack a cardboard 1 or 2 packs.

Suppositories for rectal application. 1 supp. contains:

Imunofan in cancer 100 mcg

excipients: purified water, glycine solid fat tween 80 

in a contour acheikova package 5 or 10 PCs in a pack a cardboard 1 or 2 packs.

Spray nasal 1 dose contains:

Imunofan in cancer 50 mcg

auxiliary substances: sodium chloride benzalkonium chloride glycine sodium edetate (Trilon B) purified water 

in a plastic bottle with a metering device of 8.5 ml in a cardboard pack 1 bottle.

Description pharmaceutical form:

Solution for injection: colorless transparent liquid.

Suppositories: homogeneous suppositories from white to white with a yellowish sheen color, torpedo-shaped. Allowed a weak specific smell.

Nasal spray: transparent, or slabohopalestirutaya colorless, or slightly yellowish liquid. Allowed a weak specific smell.

Description pharmacological action:

The drug has immunoregulatory, detoxification, hepatoprotective effect and causes the inactivation of free radical and peroxide compounds. Corrigiruet the immune system, restores the balance of oxidative-antioxidative reactions of the body and helps to overcome multidrug resistance of tumor cells mediated protein transmembrane transport pump cells.

The effect of the drug begins to develop within 2-3 hours (fast phase) and lasts up to 4 months (average and slow phases).

During the fast phase (duration up to 2-3 days) is primarily a detoxification effect is enhanced antioxidant protection of the organism due to stimulation of production of ceruloplasmin, lactoferrin, catalase activity the drug normalizes lipid peroxidation, inhibits the breakdown of phospholipids of cell membranes and the synthesis of arachidonic acid with subsequent reduction of blood cholesterol and the production of inflammatory mediators. Toxic and infectious liver disease the drug prevents cytolysis, reduces the activity of transaminases and bilirubin level in serum.

During the middle phase (begins after 2-3 days, duration up to 7-10 days) allows amplification reactions phagocytosis and destruction of intracellular bacteria and viruses.

During the slow phase (begins to grow for 7-10 days, duration up to 4 months) is immunoregulatory effect Imunofana — restoration of disturbed indices of cellular and humoral immunity. In this period there was normalization of immunoregulatory index, there is increase in production of specific antibodies. The effects of the drug on the production of specific antiviral and antibacterial antibodies is equivalent to the action of therapeutic vaccines. Unlike the latter, the drug has no significant effect on the production of reaginovykh antibodies of class IgE and does not increase the reaction of immediate hypersensitivity Imunofan in cancer stimulates the formation of IgA in its congenital deficiency.

Imunofan in cancer effectively inhibits multidrug resistance of tumor cells and increases their sensitivity to the action of chemotherapy drugs.

Indications:

Solution for I/m and s/to the introduction and rectal suppositories

For adults and children over 2 years of age (prophylaxis and treatment):

• immunodeficiency and toxic status
  
• chronic inflammatory diseases of different etiology.
  

Adult — as an adjuvant in vaccination against bacterial and viral infections.

Metered-dose nasal spray:

For adults and children over 2 years of age (prophylaxis and treatment):

• immunodeficiency and toxic status
  
• acute and chronic infectious and inflammatory diseases.
  

Contraindications:

• hypersensitivity
  
• children up to age 2 years.
  

For solution for I/m and s/to the introduction of suppositories and rectal (optional) — the pregnancy complicated by RH-conflict.

Application of pregnancy and breast-feeding:

Solution for I/m and s/to the introduction and rectal suppositories is contraindicated in pregnancy complicated by RH-conflict.

Due to a lack of knowledge of nasal spray should be used with caution during pregnancy and lactation.

Side effects:

The individual intolerance.

Drug interactions:

For all dosage forms: can be combined with anti-inflammatory (steroid and non-steroidal) drugs (action Imunofana not depend on products ???2).

Solution for injection: cases of interaction Imunofana with other drugs not registered.

Nasal spray: increases the effectiveness of other types of drug therapy the use of imunofana helps overcome resistance to therapy corticosteroids.

Method of application and dose:

P/to or/m, rectally, intranasally.

Solution for injection: rates, time and daily dose of 50 micrograms.

Suppositories: single (daily) dose of 100 mg (1 supp.).

Nasal spray: when using the bottle upright, spray up. Remove the protective cap from the dispenser. Before first use to fill the metering pump by pressing the wide rim of the spray 3-4 times. Insert the spray into the nasal passage in the vertical position of the head. Press the wide rim of the atomizer until it stops. One dose contains 50 mcg of imunofana. Daily dose should not exceed 200 mcg.

In the treatment of cancer patients in the radical scheme of the combined treatment (chemoradiotherapy and surgery):

- 1 time a day, daily, course of treatment — 8-10 injections (8-10 supp. or 1 dose in each nostril for 8-10 days) prior to chemoradiotherapy and surgery followed by a repetition of the courses during the treatment period, with an interval of 15-20 days.

Patients with generalized tumor process (stage III–IV) of different localization in the form of a complex or symptomatic therapy:

- 1 time a day, daily, course of treatment — 8-10 injections (8-10 supp. or 1 dose in each nostril for 8-10 days) with a break of 15-20 days and repeat courses during the entire period of follow-up treatment.

In children with malignant diseases of the hematopoietic and lymphoid systems:

- 1 time a day, daily, course of treatment — 10-20 injections (10-20 supp.). The drug is administered during the entire course of radiotherapy and after its termination to prevent the development of toxemia.

In the treatment of acute and chronic infectious inflammatory diseases accompanied by symptoms of intoxication and immunodeficiency:

- 1 dose (50 mcg) in each nostril 2 times a day for 10-15 days.

In complex therapy of children with papillomatosis of the larynx and oropharynx:

- 1 time a day, daily, course of treatment — 10 injections (10 supp.).

Opportunistic infections (CMV and herpes infection, toxoplasmosis, chlamydia, Pneumocystis, cryptosporidiosis):

- 1 time a day, daily, course of treatment — 15-20 injections (15-20 supp.) or 1 dose in each nostril 2 times a day, daily, course of treatment — 10-15 days. If necessary, courses may be repeated within 2-4 weeks.

In the treatment of HIV infection:

- 1 time a day, daily, course of treatment — 15-20 injections (15-20 supp. or 1 dose in each nasal passage within 10 to 15 days). If necessary, possibly re courses within 2-4 weeks.

In chronic viral hepatitis and chronic brucellosis:

- 1 time a day, daily, course of treatment — 15-20 injections (15-20 supp. or 1 dose in each nasal passage within 10 to 15 days) to prevent relapse should be repeated courses in 2-3 months (for the nasal spray after 4 to 6 months).

In diphtheria:

- 1 time a day, daily, course of treatment — 8-10 injections (8-10 supp.). When diphtheria bacteria carrying — 1 time in 3 days. The treatment course is 3-5 injections (3-5 supp.).

In the treatment of burns III–IV degree with the phenomena of a toxemia, a septicotoxemia, in surgical patients with septic endocarditis, nonhealing wounds of the extremities, purulent-septic complications

- 1 time a day, daily, course of treatment — 7-10 injections (7-10 supp.), if necessary, treatment should continue for up to 20 injection (20 supp.).

In broncho-obstructive syndrome, holetsistopankreatit, rheumatoid arthritis:

- 1 time in 3 days, the treatment course of 8-10 injections (8-10 supp.), if necessary, treatment should continue for up to 20 injection (20 supp.) according to the same scheme.

In the treatment of psoriasis:

- 1 time a day, daily, course of treatment — 15-20 injections (15-20 supp.).

Vaccination: adults — once a day of vaccination.

Special instructions:

As a result of activation of phagocytosis possible short-term aggravation of foci of chronic inflammation, supported by the persistence of viral or bacterial antigens.